Today, more and more complementary therapies are being integrated into care plans for patients with prostate cancer. Read the article here.
A recent large U.S. study designed to gauge the health benefits of vitamin D and fish oil supplements concludes that the omega-3 oil can dramatically reduce the odds of a heart attack while vitamin D’s benefits seem to come from lowering the risk of death from cancer. Neither vitamin D nor fish oil lowered the odds of stroke or of getting cancer in the first place in the trial. Read the article here.
Several recent short-term intervention studies failed to show vitamin E supplementation was protective against the development of various cancers, most notably lung and prostate cancer. In fact, in the SELECT study, individuals taking vitamin E supplements showed a 17 percent higher incidence of prostate cancer. A review of the literature suggests while the recent research on vitamin E may be conflicting, evidence supporting the anti-cancer properties of a specific form of vitamin E known as vitamin E succinate (alpha-tocopheryl succinate) is promising. Read the article.
Although popular, such supplements do not appear to lower the risk for experiencing radiation treatment side effects; the risk that localized cancer will spread; or the risk that prostate cancer patients will die from their disease, researchers found. “We suspected that these pills were junk. Our study confirmed our suspicion,” said study lead author Dr. Nicholas Zaorsky, resident physician in radiation oncology at the Fox Chase Cancer Center in Philadelphia. Read the article.
In a groundbreaking laboratory study, a research team at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has found that a non-toxic oral agent that is also consumed as an over-the-counter dietary supplement in Europe and Asia for improving liver health, is highly effective in both preventing and treating prostate cancer. Additionally the agent was able to halt the metastatic spread of the disease. “We found that 4-methylumbelliferone (4-MU) was able to block a key signaling pathway that triggers the development, growth and metastasis of prostate cancer,” said the study’s principal investigator Vinata B. Lokeshwar, …